Press release
Diabetic Nephropathy Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Daiichi Sankyo, Teijin Pharma, CSL Behring, Goldfinch Bio, Boehringer Ingelheim, Curacle Co., Ltd., Bayer, Boehringer
To Know in detail about the Diabetic Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Nephropathy Market Forecast
https://www.delveinsight.com/sample-request/diabetic-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Diabetic Nephropathy Market Report:
• The Diabetic Nephropathy market size was valued approximately USD 9.2 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The overall number of existing cases of Diabetic Nephropathy in the 7 Major Markets (7MM) was projected to be 27,996,925 in 2021 and is anticipated to rise throughout the study period from 2019 to 2032.
• In the European Union Five (EU5) countries, there were 10,323,572 prevalent cases of Diabetic Nephropathy in 2021, and this number is projected to increase during the study period from 2019 to 2032.
• The overall number of existing cases of Diabetic Nephropathy in Japan was approximated to be 4,195,914 in 2021 and is projected to see an increase during the forecast period from 2022 to 2032.
• In the United States, there were a greater number of Diabetic Nephropathy cases observed in the age group of 18-64 years compared to the age group of ≥65 years, with 8,490,787 and 4,986,653 cases, respectively, in 2021. These instances are anticipated to rise during the forecast period.
• Key Diabetic Nephropathy Companies: Daiichi Sankyo, Teijin Pharma, CSL Behring, Goldfinch Bio, Boehringer Ingelheim, Curacle Co., Ltd., Bayer, Boehringer Ingelheim, Pfizer, Mitsubishi Tanabe Pharma, Novartis, PhytoHealth Corporation, Eli Lilly and Company, BioStratum, Dong Wha Pharmaceutical, Vascular Pharmaceutical, Otsuka Beijing Research Institute, Fresenius Kabi, Yuhan Corporation, Biogen, NephroGenex, Inc., Pfizer, Glycadia, Boehringer Ingelheim, and others
• Key Diabetic Nephropathy Therapies: Esaxerenone, TMX-049, CSL346, GFB-887, BI 685509, CU01-1001, BAY94-8862, Telmisartan, PF-00489791, Canagliflozin, Nidufexor, PH3, LY3016859, Pyridorin (pyridoxamine dihydrochloride), DW1029M, VPI-2690B, Probucol, Anplag(Sarpogrelate), RTA 402 (Bardoxolone Methyl), CS-3150, Pyridoxamine Dihydrochloride, PF-04634817, GLY-230, telmisartan, and others
• The Diabetic Nephropathy epidemiology based on gender analyzed that Diabetic Nephropathy affects males more than the females
• The Diabetic Nephropathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Nephropathy pipeline products will significantly revolutionize the Diabetic Nephropathy market dynamics.
Diabetic Nephropathy Overview
Diabetic nephropathy is a type of progressive kidney disease that occurs as a complication of diabetes. It is a long-term complication that affects people with both type 1 and type 2 diabetes. Diabetic nephropathy is characterized by damage to the small blood vessels in the kidneys, leading to impaired kidney function.
Get a Free sample for the Diabetic Nephropathy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/diabetic-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Diabetic Nephropathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Diabetic Nephropathy Epidemiology Segmentation:
The Diabetic Nephropathy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Diabetic Nephropathy
• Prevalent Cases of Diabetic Nephropathy by severity
• Gender-specific Prevalence of Diabetic Nephropathy
• Diagnosed Cases of Episodic and Chronic Diabetic Nephropathy
Download the report to understand which factors are driving Diabetic Nephropathy epidemiology trends @ Diabetic Nephropathy Epidemiology Forecast
https://www.delveinsight.com/sample-request/diabetic-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Diabetic Nephropathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Nephropathy market or expected to get launched during the study period. The analysis covers Diabetic Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Diabetic Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Diabetic Nephropathy Therapies and Key Companies
• Esaxerenone: Daiichi Sankyo
• TMX-049: Teijin Pharma
• CSL346: CSL Behring
• GFB-887: Goldfinch Bio
• BI 685509: Boehringer Ingelheim
• CU01-1001: Curacle Co., Ltd.
• BAY94-8862: Bayer
• Telmisartan: Boehringer Ingelheim
• PF-00489791: Pfizer
• Canagliflozin: Mitsubishi Tanabe Pharma
• Nidufexor: Novartis
• PH3: PhytoHealth Corporation
• LY3016859: Eli Lilly and Company
• Pyridorin (pyridoxamine dihydrochloride): BioStratum
• DW1029M: Dong Wha Pharmaceutical
• VPI-2690B: Vascular Pharmaceutical
• Probucol: Otsuka Beijing Research Institute
• Anplag(Sarpogrelate): Yuhan Corporation
• RTA 402 (Bardoxolone Methyl): Biogen
• CS-3150: Daiichi Sankyo, Inc.
• Pyridoxamine Dihydrochloride: NephroGenex, Inc.
• PF-04634817: Pfizer
• GLY-230: Glycadia
• telmisartan: Boehringer Ingelheim
Discover more about therapies set to grab major Diabetic Nephropathy market share @ Diabetic Nephropathy Treatment Landscape
https://www.delveinsight.com/sample-request/diabetic-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Diabetic Nephropathy Market Drivers
• Increased prevalence of diabetes and Diabetic Kidney Disease
• Annual screening programs
• Multidisciplinary Care
Diabetic Nephropathy Market Barriers
• Heterogeneous nature of the disease
• Lack of awareness among the patients and primary care physician
• Poor access to health insurance and healthcare
• Diabetic Nephropathy Treatment challenges
Scope of the Diabetic Nephropathy Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Diabetic Nephropathy Companies: Daiichi Sankyo, Teijin Pharma, CSL Behring, Goldfinch Bio, Boehringer Ingelheim, Curacle Co., Ltd., Bayer, Boehringer Ingelheim, Pfizer, Mitsubishi Tanabe Pharma, Novartis, PhytoHealth Corporation, Eli Lilly and Company, BioStratum, Dong Wha Pharmaceutical, Vascular Pharmaceutical, Otsuka Beijing Research Institute, Fresenius Kabi, Yuhan Corporation, Biogen, NephroGenex, Inc., Pfizer, Glycadia, Boehringer Ingelheim, and others
• Key Diabetic Nephropathy Therapies: Esaxerenone, TMX-049, CSL346, GFB-887, BI 685509, CU01-1001, BAY94-8862, Telmisartan, PF-00489791, Canagliflozin, Nidufexor, PH3, LY3016859, Pyridorin (pyridoxamine dihydrochloride), DW1029M, VPI-2690B, Probucol, Anplag(Sarpogrelate), RTA 402 (Bardoxolone Methyl), CS-3150, Pyridoxamine Dihydrochloride, PF-04634817, GLY-230, telmisartan, and others
• Diabetic Nephropathy Therapeutic Assessment: Diabetic Nephropathy current marketed and Diabetic Nephropathy emerging therapies
• Diabetic Nephropathy Market Dynamics: Diabetic Nephropathy market drivers and Diabetic Nephropathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Diabetic Nephropathy Unmet Needs, KOL's views, Analyst's views, Diabetic Nephropathy Market Access and Reimbursement
To know more about Diabetic Nephropathy companies working in the treatment market, visit @ Diabetic Nephropathy Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/diabetic-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Diabetic Nephropathy Market Report Introduction
2. Executive Summary for Diabetic Nephropathy
3. SWOT analysis of Diabetic Nephropathy
4. Diabetic Nephropathy Patient Share (%) Overview at a Glance
5. Diabetic Nephropathy Market Overview at a Glance
6. Diabetic Nephropathy Disease Background and Overview
7. Diabetic Nephropathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Diabetic Nephropathy
9. Diabetic Nephropathy Current Treatment and Medical Practices
10. Diabetic Nephropathy Unmet Needs
11. Diabetic Nephropathy Emerging Therapies
12. Diabetic Nephropathy Market Outlook
13. Country-Wise Diabetic Nephropathy Market Analysis (2019-2032)
14. Diabetic Nephropathy Market Access and Reimbursement of Therapies
15. Diabetic Nephropathy Market Drivers
16. Diabetic Nephropathy Market Barriers
17. Diabetic Nephropathy Appendix
18. Diabetic Nephropathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Diabetic Nephropathy Pipeline https://www.delveinsight.com/report-store/diabetic-nephropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Diabetic Nephropathy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Diabetic Nephropathy market. A detailed picture of the Diabetic Nephropathy pipeline landscape is provided, which includes the disease overview and Diabetic Nephropathy treatment guidelines.
Diabetic Nephropathy Epidemiology https://www.delveinsight.com/report-store/diabetic-nephropathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Diabetic Nephropathy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Diabetic Nephropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.
Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Nephropathy Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Daiichi Sankyo, Teijin Pharma, CSL Behring, Goldfinch Bio, Boehringer Ingelheim, Curacle Co., Ltd., Bayer, Boehringer here
News-ID: 3358811 • Views: …
More Releases from DelveInsight Business Research
DelveInsight Enables Strategic Partner Identification for Oncology Biopharma Adv …
DelveInsight, a leading life science market research and strategic consulting firm, today announced the successful completion of a comprehensive Partner Identification and Assessment Program for a US-based mid-sized pharmaceutical company developing a novel clinical-stage oncology asset targeting Head and Neck Cancer. The engagement focused on identifying co-development and commercialization partners across the United States and European markets to accelerate late-stage clinical progress and market entry.
Discover how your oncology asset can…
DelveInsight Facilitates Global Out-Licensing Opportunity for Proprietary Neonat …
DelveInsight Business Research LLP, a leading healthcare strategic intelligence and consulting firm, today announced the successful completion of an out-licensing opportunity assessment for a Sweden-based biopharmaceutical innovator specializing in high-quality neonatal mesenchymal stem cells (MSCs). The engagement was focused on identifying global licensing partners with strong commercialization capabilities, with a strategic emphasis on Asia-Pacific expansion, where regenerative medicine markets are witnessing accelerated regulatory support and clinical adoption.
The client, a clinical-stage…
Yellow Fever Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluat …
(Las Vgas, Nevada, United States) As per DelveInsight's assessment, globally, Yellow Fever pipeline constitutes 3+ key companies continuously working towards developing 3+ Yellow Fever treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Yellow Fever Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers…
Influenza A Infections Market Positioned for Accelerated Development Through 203 …
The Influenza A Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Influenza A Infections pipeline products will significantly revolutionize the Influenza A Infections market dynamics.
DelveInsight's "Influenza A Infections Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Influenza A Infections, historical and forecasted epidemiology as well as the Influenza A…
More Releases for Diabetic
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Leading Element Driving Change in the Diabetic Footwear Market in 2025: Rising D …
Which drivers are expected to have the greatest impact on the over the diabetic footwear market's growth?
The surge in people with diabetes will spur the expansion of the diabetic footwear market in the future. Diabetes, characterised by high blood sugar levels, is a long-term health issue. Diabetic footwear can prevent severe foot-related issues caused by diabetes and offer several advantages such as enhanced blood flow, ample space for the toes,…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
